ArticleActa neurologica Scandinavica2011
The Creutzfeldt-Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression.
Article in Acta neurologica Scandinavica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02480725 (The Role of the Coagulation Pathway at the Synapse in Prion Diseases), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of the Coagulation Pathway at the Synapse in Prion Diseases
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Characterization of Laboratory-Confirmed Creutzfeldt-Jakob Disease From 3 Ontario Tertiary Care Centers Between 2012 and 2022: A Retrospective Cohort Study.Open forum infectious diseases · 2024Article
- Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease.Journal of neurology, neurosurgery, and psychiatry · 2022Article
- Familial Creutzfeldt-Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course.Journal of neurology · 2020Article
- Disease duration in E200K familial Creutzfeldt-Jakob disease is correlated with clinical, radiological, and laboratory variables.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- Clinical radiological correlation in E200K familial Creutzfeldt-Jakob disease.Journal of neural transmission (Vienna, Austria : 1996) · 2016Article
- Unusual presentations in patients with E200K familial Creutzfeldt-Jakob disease.European journal of neurology · 2016Article
- Familial Creutzfeldt-Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD.Journal of neurology · 2015Article
- Characterization of sleep disorders in patients with E200K familial Creutzfeldt-Jakob disease.Journal of neurology · 2015Article
- Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease.Journal of neurology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
objectivesTo develop a scale sensitive for the neurological manifestations of Creutzfeldt-Jakob disease (CJD).
methodsA 26-item CJD neurological status scale (CJD-NS) was created based on characteristic disease manifestations. Each sign was assigned to one of eight neurological systems to calculate a total scale score (TSS) and a system involvement score (SIS). The scale was administered to 37 CJD patients, 101 healthy first-degree relatives of the patients and 14 elderly patients with Parkinson's disease (PD).
resultsThe mean TSS (±SD) was significantly higher in patients with CJD (13.19 ± 5.63) compared with normal controls (0.41 ± 0.78) and PD patients (9.71 ± 3.05). The mean SIS was also significantly different between the CJD (5.19 ± 1.22) and PD (2.78 ± 1.18 P ≤ 0.01) groups reflecting the disseminated nature of neurological involvement in CJD. Using a cutoff of TSS > 4 yielded a sensitivity of 97% for CJD, and specificity of 100% against healthy controls. All individual items showed excellent specificity against healthy subjects, but sensitivity was highly variable. Repeat assessments of CJD patients over 3-9 months revealed a time-dependent increase in both the TSS and the SIS reflecting the scale's ability to track disease progression.
conclusionsThe CJD-NS scale is sensitive to neurological signs and their progression in CJD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.